Aristolochic acid A (Aristolochic acid I; TR 1736) 是植物提取物 Aristolochic acids 的主要成分，其存在于Aristolochia和Asarum草本植物中。Aristolochic acid A 显着降低激活蛋白1 (AP-1) 和NF-κB活性。Aristolochic acid A 降低人细胞中膀胱癌相关BLCAP基因表达。
| 生物活性 | Aristolochic acid A (Aristolochic acid I; TR 1736) is the main component of plant extract Aristolochic acids, which are found in various herbalplantsof genusAristolochiaandAsarum. Aristolochic acid A significantly reduces both activator protein 1 (AP-1) andNF-κBactivities. Aristolochic acid A reducesBLCAPgene expression in human cell lines[1]. |
体外研究
(In Vitro) | Aristolochic acid A (150, 200 μM, 24 hours) inhibits the cell viabilities of kidney cells HEK293 and HK-2[1].
Aristolochic acid A (100, 200 μM, 24 hours) causes a concentration-dependent decrease in bladder cancer-associated protein (BLCAP) mRNA levels in kidney cells (HEK 293 and HK-2) , and bladder cancer cell line (HT-1376)[1].
Aristolochic acid A (100, 200 μM, 24 hours) weakens the BLCAP protein signals in a dose-dependent manner in both HEK293 and HT-1376 cells[1].
Cell Viability Assay[1] | Cell Line: | Kidney cells (HEK 293 and HK-2) | | Concentration: | 50, 100, 150, 200 μM | | Incubation Time: | 24 hours | | Result: | The cell viabilities of HEK293 and HK-2 were lower than that of vehicle-treated cultures until 150 μM and 200 μM. |
RT-PCR[1] | Cell Line: | Kidney cells (HEK 293 and HK-2), and bladder cancer cell line (HT-1376) | | Concentration: | 100, 200 μM | | Incubation Time: | 24 hours | | Result: | Down regulated the levels ofBLCAPmRNA. |
Western Blot Analysis[1] | Cell Line: | HEK293 and HT-1376 cells | | Concentration: | 100, 200 μM | | Incubation Time: | 24 hours | | Result: | Reduced the BLCAP protein expression in a dose-dependent manner. |
|
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 中文名称 | |
| 结构分类 | |
| 来源 | - Plants
- Aristolochiaceae
- Aristolochia debilis Sieb. et Zucc.
|
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
| 溶解性数据 | In Vitro: DMSO : 16.67 mg/mL(48.85 mM;Need ultrasonic) 配制储备液 | 1 mM | 2.9302 mL | 14.6512 mL | 29.3023 mL | | 5 mM | 0.5860 mL | 2.9302 mL | 5.8605 mL | | 10 mM | 0.2930 mL | 1.4651 mL | 2.9302 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month (protect from light)。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.08 mg/mL (6.09 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (6.09 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。 *以上所有助溶剂都可在本网站选购。
|
m.cnreagent.com